Please login to the form below

Not currently logged in
Email:
Password:

Lusduna

This page shows the latest Lusduna news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Merck & Co's Lantus biosimilar

CHMP recommends Merck & Co's Lantus biosimilar

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lusduna (insulin glargine) for the treatment of diabetes mellitus, after it showed comparable quality, safety and ... Lusduna is now one step closer to European

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    The termination comes as a consequence of patent infringement litigation which has placed a stay on the FDA’s approval of the biosimilar, Lusduna Nexvue, in the US. ... $307m. Samsung Bioepis/. Merck &Co. Lusduna Nexvue follow‐on biologic. Termination

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics